Last reviewed 2026-05-14 · How we verify

CV0801 mRNA COVID-19 Vaccine

GlaxoSmithKline · Phase 2 active Biologic

CV0801 mRNA COVID-19 Vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development.

At a glance

Generic name	CV0801 mRNA COVID-19 Vaccine
Sponsor	GlaxoSmithKline
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CV0801 mRNA COVID-19 Vaccine CI brief — competitive landscape report
CV0801 mRNA COVID-19 Vaccine updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about CV0801 mRNA COVID-19 Vaccine

What is CV0801 mRNA COVID-19 Vaccine?

CV0801 mRNA COVID-19 Vaccine is a Biologic drug developed by GlaxoSmithKline.

Who makes CV0801 mRNA COVID-19 Vaccine?

CV0801 mRNA COVID-19 Vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is CV0801 mRNA COVID-19 Vaccine in?

CV0801 mRNA COVID-19 Vaccine is in Phase 2.

Manufacturer: GlaxoSmithKline — full pipeline
Compare: CV0801 mRNA COVID-19 Vaccine vs similar drugs
Pricing: CV0801 mRNA COVID-19 Vaccine cost, discount & access